Loading organizations...
Based in Fishers, Indiana, BiomEdit is a biotechnology company that discovers and develops microbiome-derived biome-actives, novel probiotics, and engineered microbial medicines for the animal health industry. The organization utilizes synthetic biology to create biological alternatives to antibiotics and optimize livestock health across pigs, chickens, fish, and cattle. To support ongoing product development, the firm leverages a proprietary microbiome library built from analyzing over 10,000 unique samples across 7,500 animals. The venture-backed startup secured $40 million in initial Series A financing from lead investors including Viking Global Investors, Anterra Capital, and Ferment. Additionally, the enterprise received a $4.5 million grant from the Bill & Melinda Gates Foundation and maintains strategic commercial partnerships with Ginkgo Bioworks and Nutreco. BiomEdit was officially founded in 2022 as a carve-out from Elanco Animal Health by chief executive officer Aaron Schacht.
BiomEdit has raised $24.6M across 2 funding rounds.
BiomEdit has raised $24.6M in total across 2 funding rounds.
BiomEdit has raised $24.6M across 2 funding rounds. Most recently, it raised $20.1M Grant / Series B in July 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 18, 2025 | $20.1M Grant | Brett Wong | — | Announced |
| Nov 2, 2023 | $4.5M Grant | Bill & Melinda Gates Foundation | — | Announced |
BiomEdit has raised $24.6M in total across 2 funding rounds.
BiomEdit's investors include Brett Wong, Bill & Melinda Gates Foundation.
